Contribution of LAT1-4F2hc in Urological Cancers via Toll-like Receptor and Other Vital Pathways

  • Xue Zhao
    Department of Urology, Chiba University Graduate School of Medicine, Chiba 260-8670, Japan
  • Shinichi Sakamoto
    Department of Urology, Chiba University Graduate School of Medicine, Chiba 260-8670, Japan
  • Maihulan Maimaiti
    Department of Tumor Pathology, Chiba University Graduate School of Medicine, Chiba 260-8670, Japan
  • Naohiko Anzai
    Department of Pharmacology, Chiba University Graduate School of Medicine, Chiba 260-8670, Japan
  • Tomohiko Ichikawa
    Department of Urology, Chiba University Graduate School of Medicine, Chiba 260-8670, Japan

説明

<jats:p>Tumor cells are known for their ability to proliferate. Nutrients are essential for rapidly growing tumor cells. In particular, essential amino acids are essential for tumor cell growth. Tumor cell growth nutrition requires the regulation of membrane transport proteins. Nutritional processes require amino acid uptake across the cell membrane. Leucine, one of the essential amino acids, has recently been found to be closely associated with cancer, which activate mTOR signaling pathway. The transport of leucine into cells requires an L-type amino acid transporter protein 1, LAT1 (SLC7A5), which requires the 4F2 cell surface antigen heavy chain (4F2hc, SLC3A2) to form a heterodimeric amino acid transporter protein complex. Recent evidence identified 4F2hc as a specific downstream target of the androgen receptor splice variant 7 (AR-V7). We stressed the importance of the LAT1-4F2hc complex as a diagnostic and therapeutic target in urological cancers in this review, which covered the recent achievements in research on the involvement of the LAT1-4F2hc complex in urinary system tumors. In addition, JPH203, which is a selective LAT1 inhibitor, has shown excellent inhibitory effects on the proliferation in a variety of tumor cells. The current phase I clinical trials of JPH203 in patients with biliary tract cancer have also achieved good results, which is the future research direction for LAT1 targeted therapy drugs.</jats:p>

収録刊行物

  • Cancers

    Cancers 14 (1), 229-, 2022-01-04

    MDPI AG

被引用文献 (1)*注記

もっと見る

参考文献 (126)*注記

もっと見る

関連プロジェクト

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ